Literature DB >> 16341685

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

P Rossing1.   

Abstract

Diabetic nephropathy is a major problem for patients and health care systems. The costs of treatment remain high. To confront the ongoing challenge, we need to identify individuals at high risk for initiation and progression of this devastating complication. Risk factors include genetic markers; constitutional factors such as low birthweight; haemodynamic factors, including activation of the RAS system and hypertension; metabolic factors such as glycaemia; and additional factors such as urinary AER and smoking. Modifiable risk factors should be treated aggressively. Potential new markers of risk include indices of increased inflammation, changes in coagulation, endothelial dysfunction, growth factors and cytokines. Application of such markers may in time improve risk assessment and allow new treatment targets to be identified. Interventions that aim to achieve strict glycaemic control and blockade of the renin-angiotensin system have been shown to be effective in clinical trials and are feasible in clinical practice. The 'natural history' of diabetic nephropathy can be transformed if these strategies of intensive screening and care are applied, leading both to a lower incidence of diabetic nephropathy and to an improved outcome, with survival exceeding 20 years from onset of overt proteinuria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341685     DOI: 10.1007/s00125-005-0077-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  113 in total

1.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Authors:  Kasper Rossing; Per K Christensen; Berit R Jensen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

Review 2.  Biochemical risk markers: a novel area for better prediction of renal risk?

Authors:  Erik M Stuveling; Stephan J L Bakker; Hans L Hillege; Paul E de Jong; Reinold O B Gans; Dick de Zeeuw
Journal:  Nephrol Dial Transplant       Date:  2005-03       Impact factor: 5.992

3.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes.

Authors:  L J Scott; J H Warram; L S Hanna; L M Laffel; L Ryan; A S Krolewski
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

5.  Short stature and diabetic nephropathy.

Authors:  P Rossing; L Tarnow; F S Nielsen; S Boelskifte; B M Brenner; H H Parving
Journal:  BMJ       Date:  1995-02-04

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

Authors:  Trevor J Orchard; Yue-Fang Chang; Robert E Ferrell; Nancy Petro; Demetrius E Ellis
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

8.  Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.

Authors:  J Yip; M B Mattock; A Morocutti; M Sethi; R Trevisan; G Viberti
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

9.  Is diabetic nephropathy an inherited complication?

Authors:  K Borch-Johnsen; K Nørgaard; E Hommel; E R Mathiesen; J S Jensen; T Deckert; H H Parving
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

10.  Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents.

Authors:  D Daneman; C H Crompton; J W Balfe; E B Sochett; A Chatzilias; B R Cotter; D H Osmond
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612

View more
  29 in total

Review 1.  Microvascular disease in children and adolescents with type 1 diabetes and obesity.

Authors:  M Loredana Marcovecchio; Francesco Chiarelli
Journal:  Pediatr Nephrol       Date:  2010-08-19       Impact factor: 3.714

2.  Assessment of kidney function: UACR--two risk markers or a 24 h collection in a minute?

Authors:  Peter Rossing
Journal:  Nat Rev Nephrol       Date:  2012-05-08       Impact factor: 28.314

3.  The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood.

Authors:  Cosimo Giannini; Ebe D'Adamo; Tommaso de Giorgis; Valentina Chiavaroli; Alberto Verrotti; Francesco Chiarelli; Angelika Mohn
Journal:  Pediatr Nephrol       Date:  2011-08-26       Impact factor: 3.714

4.  Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?

Authors:  Peter Rossing
Journal:  Nat Rev Nephrol       Date:  2013-02-05       Impact factor: 28.314

5.  The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes.

Authors:  R Klein; M D Knudtson; B E K Klein; B Zinman; R Gardiner; S Suissa; A R Sinaiko; S M Donnelly; P Goodyer; T Strand; M Mauer
Journal:  Diabetologia       Date:  2010-05-01       Impact factor: 10.122

6.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

Authors:  G Targher; L Bertolini; M Chonchol; S Rodella; G Zoppini; G Lippi; L Zenari; E Bonora
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

Review 7.  Why do some patients with type 1 diabetes live so long?

Authors:  Larry A Distiller
Journal:  World J Diabetes       Date:  2014-06-15

8.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Michel Chonchol; Lorenzo Bertolini; Stefano Rodella; Luciano Zenari; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

9.  Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation.

Authors:  Jawl-Shan Hwang; Tsu-Lan Wu; S C Chou; C Ho; Pi-Yueh Chang; Kuo-Chien Tsao; Jeng-Yi Huang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

10.  Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus.

Authors:  Yaomin Hu; Pamela J Kaisaki; Karène Argoud; Steven P Wilder; Karin J Wallace; Peng Y Woon; Christine Blancher; Lise Tarnow; Per-Henrik Groop; Samy Hadjadj; Michel Marre; Hans-Henrik Parving; Martin Farrall; Roger D Cox; Mark Lathrop; Nathalie Vionnet; Marie-Thérèse Bihoreau; Dominique Gauguier
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.